Spotlight
Topics
DI Executive
Subscribe
- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
AMA Issues New CPT Code for Intraoperative Fluorescence Breast Imaging
Going into effect in 2015, the Category III CPT add-on code may facilitate broader access to the use of fluorescence imaging for assessing margins after lumpectomies for signs of residual breast cancer.
Reportedly over one-third of women undergoing lumpectomy procedures have re-excisions due to positive margins.1 However, a newly issued CPT code may enable greater access to real-time intraoperative fluorescence imaging to detect residual breast cancer.
The Category III CPT add-on code 0945T, which will be effective on January 1, 2025, can be utilized for intraoperative margin assessment with fluorescence imaging after the performance of lumpectomy procedures.2
A newly issued CPT add-on code for fluorescence imaging margin assessment during lumpectomy procedures may facilitate broader access to the LumiSystem (Lumicell), a fluorescence imaging system that was approved by the FDA earlier this year. (Image courtesy of Lumicell.)
The CPT add-on code could facilitate broader access to the LumiSystem (Lumicell), a fluorescence imaging system that was approved by the FDA earlier this year. The LumiSystem, which includes the Lumicell Direct Visualization System and the optical imaging agent pegulicianine (Lumisight), has an 84 percent accuracy rate for detecting post-lumpectomy residual breast cancer, according to Lumicell.
“This new CPT code demonstrates positive momentum towards improving patient access to LumiSystem, which will have significant impact on breast cancer surgical outcomes for patients,” said Peter Blumencranz, M.D., the medical director of the BayCare Oncology Service Line and the Comprehensive Breast Care Center of Tampa Bay.
Lumicell noted the LumiSystem is expected to launch in the fourth quarter of 2024.
References
1. Dupont E, Tsangaris T, Garcia-Cantu C, et al. Resection of cavity shave margins in stage 0-III breast cancer patients undergoing breast conserving surgery: a prospective multicenter randomized controlled trial. Ann Surg. 2021;273(5):876-881.
2. Lumicell. Lumicell announces new category III CPT code for intraoperative fluorescence imaging margin assessment in support of market launch. Business Wire. Available at: https://www.businesswire.com/news/home/20240715471843/en/Lumicell-Announces-New-Category-III-CPT%C2%AE-Code-for-Intraoperative-Fluorescence-Imaging-Margin-Assessment-in-Support-of-Market-Launch . Published July 15, 2024. Accessed July 15, 2024.
Recent Videos
Related Content
Interventional Radiology-Led Study Shows Benefits of CT-Guided Cryoablation for Soft Tissue Sarcoma
August 1st 2024Article
In a study involving 217 percutaneous cryoablation procedures for treating recurrent or metastatic soft tissue sarcoma in 141 patients, researchers noted an 86 percent rate of local progression-free survival and a 2 percent complication rate.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Podcast
Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
New Literature Review Finds ChatGPT Effective in Radiology in 84 Percent of Studies
April 29th 2024Article
While noting a variety of pitfalls with the chatbot ranging from hallucinations to improper citations, the review authors found the use of ChatGPT in radiology demonstrated “high performance” in 37 out of 44 studies.
